Search results
Showing 136 to 150 of 161 results for prostate cancer
Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)
This evidence summary has been updated and replaced by NICE guideline NG131.
Care and support of people growing older with learning disabilities (NG96)
This guideline covers care and support for adults with learning disabilities as they grow older. It covers identifying changing needs, planning for the future, and delivering services including health, social care and housing. It aims to support people to access the services they need as they get older.
Enzalutamide for the treatment of hormone refractory prostate cancer TA316
Discontinued [GID-TA10267]
Suspected sepsis: recognition, diagnosis and early management (NG51)
This guideline covers the recognition, diagnosis and early management of suspected sepsis. It includes recommendations on recognition and early assessment, initial treatment, escalating care, finding and controlling the source of infection, early monitoring, information and support, and training and education.
Show all sections
Sections for NG51
- Overview
- Could this be sepsis?
- Face to face assessment
- Under 16s: evaluating risk and managing suspected sepsis
- Pregnant or recently pregnant people: evaluating risk and managing suspected sepsis
- Over 16s (not pregnant or recently pregnant): evaluating risk and managing suspected sepsis
- Antibiotic therapy, intravenous fluid and oxygen
- Finding and controlling the source of infection
Focal therapy using high-intensity focused ultrasound for localised prostate cancer (IPG424)
This guidance has been updated and replaced by NICE interventional procedures guidance 756.
Standards framework for shared-decision-making support tools, including patient decision aids (ECD8)
This framework sets out a series of standards to support people using patient decision aids (PDAs) in assessing the usefulness and quality of a PDA
Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)
Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.
This guidance has been updated and replaced by NICE interventional procedures guidance 752.
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA376)
This guidance has been updated and replaced by NICE technology appraisal guidance 412.
This guidance has been updated and replaced by NICE technology appraisal guidance 887.
In development [GID-TA11252] Expected publication date: TBC
This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
This guidance has been updated and replaced by NICE technology appraisal guidance 391.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
This guidance has been updated and replaced by NICE guideline CG175.